Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Liabilities (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Total Liabilities for 16 consecutive years, with $149.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 20.95% year-over-year to $149.7 million, compared with a TTM value of $149.7 million through Dec 2025, up 20.95%, and an annual FY2025 reading of $149.7 million, up 20.95% over the prior year.
  • Total Liabilities was $149.7 million for Q4 2025 at Catalyst Pharmaceuticals, up from $131.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $149.7 million in Q4 2025 and bottomed at -$375.3 million in Q2 2023.
  • Average Total Liabilities over 5 years is $19.6 million, with a median of $74.4 million recorded in 2022.
  • The sharpest move saw Total Liabilities soared 142.95% in 2022, then plummeted 1531.49% in 2023.
  • Year by year, Total Liabilities stood at $31.0 million in 2021, then soared by 142.95% to $75.2 million in 2022, then increased by 9.34% to $82.2 million in 2023, then soared by 50.52% to $123.8 million in 2024, then grew by 20.95% to $149.7 million in 2025.
  • Business Quant data shows Total Liabilities for CPRX at $149.7 million in Q4 2025, $131.4 million in Q3 2025, and $115.9 million in Q2 2025.